Image-guided biopsy: What the interventional radiologist needs to know about PET/CT

Radiographics

Volumn 32, Issue 5, 2012, Pages 1483-1501

  Kobayashi, Katsuhiro ^a   Bhargava, Peeyush ^a   Raja, Shanker ^a   Nasseri, Farbod ^a   Al Balas, Hassan A ^a,b   Smith, Darryl D ^a   George, Sharad P ^a   Vij, Meena S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; IMAGE ENHANCEMENT; IMAGE GUIDED BIOPSY; INTERVENTIONAL RADIOLOGY; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE-GUIDED BIOPSY; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOGRAPHY, INTERVENTIONAL; RADIOPHARMACEUTICALS;

EID: 84866232634     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.325115159     Document Type: Article

References (34)

1. Wahl R. Principles of cancer imaging with 18-F fluorodeoxyglucose (FDG). In: Wahl R, ed. Principles and practice of PET and PET/CT. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2009; 117-130.
2. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated- FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996;37(6):1042-1047.
3. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29(4):339-343.
4. Weisdorf DJ, Craddock PR, Jacob HS. Glycogenolysis versus glucose transport in human granulocytes: differential activation in phagocytosis and chemotaxis. Blood 1982;60(4):888-893.
5. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34(3): 414-419.
6. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32(1):47-59.
7. Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J Nucl Med 1993;34(1):75-82.
8. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine- 18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11): 1972-1980.
9. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake: the role of PET/ CT. Eur Radiol 2006;16(5):1054-1065.
10. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34(5):773-779.
11. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32(8): 1485-1490.
12. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 2006; 47(4):603-608.
13. Shreve P, Huy Bui CD. Artifacts and normal variants in FDG PET. In: Wahl R, ed. Principles and practice of PET and PET/CT. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2009; 139-168.
14. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. RadioGraphics 2004;24(6):1611-1616.
15. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. RadioGraphics 2004;24(5):1411-1431.
16. Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun 2009;30(10):763-769.
17. Chander S, Ergun EL, Zak IT, et al. Diaphragmatic and crural FDG uptake in hyperventilating patients: a rare pattern important to recognize. Clin Nucl Med 2004;29(5):296-299.
18. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16(1):173-180.
19. Gorospe L, Raman S, Echeveste J, Avril N, Herrero Y, Herna Ndez S. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun 2005;26(8):671-687.
20. Sopov V, Bernstine H, Stern D, Yefremov N, Sosna J, Groshar D. Spectrum of focal benign musculoskeletal 18F-FDG uptake at PET/CT of the shoulder and pelvis. AJR Am J Roentgenol 2009;192(4): 1029-1035.
21. Kim JM, Ryu JS, Kim TY, et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 2007;92(5):1630-1634.
22. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130(6):941-946.
23. Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999;173(1):25-29.
24. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN. FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med 2001;28(9): 1336-1340.
25. Beggs AD, Hain SF, Curran KM, O'Doherty MJ. FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 2002;29(4):542-546.
26. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004;25(7):651-656.
27. Mettler FA, Guiberteau MJ. Positron emission tomography (PET) imaging. In: Mettler FA, Guiberteau MJ, eds. Essentials of nuclear medicine imaging. 5th ed. Philadelphia, Pa: Saunders Elsevier, 2006; 359-423.
28. Govindarajan MJ, Nagaraj KR, Kallur KG, Sridhar PS. PET/CT guidance for percutaneous fine needle aspiration cytology/biopsy. Indian J Radiol Imaging 2009;19(3):208-209.
29. Klaeser B, Mueller MD, Schmid RA, Guevara C, Krause T, Wiskirchen J. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol 2009;19(7):1780-1785.
30. Tatli S, Gerbaudo VH, Feeley CM, Shyn PB, Tuncali K, Silverman SG. PET/CT-guided percutaneous biopsy of abdominal masses: initial experience. J Vasc Interv Radiol 2011;22(4):507-514.
31. Tatli S, Gerbaudo VH, Mamede M, Tuncali K, Shyn PB, Silverman SG. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology 2010;256(1):305-311.
32. Wood BJ, Zhang H, Durrani A, et al. Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol 2005;16(4):493-505.
33. Krücker J, Xu S, Glossop N, et al. Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J Vasc Interv Radiol 2007;18(9):1141-1150.
34. Krücker J, Xu S, Venkatesan A, et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol 2011;22(4):515-524.